Online inquiry

IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5745MR)

This product GTTS-WQ5745MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CEACAM5 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1048
UniProt ID P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5745MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15054MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ4414MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ6585MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ13236MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ14586MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ11349MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ8669MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ15939MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW